Structure, regulation, signaling, and targeting of abl kinases in cancer.
about
Oncogenic kinase fusions: an evolving arena with innovative clinical opportunitiesDrugs for allosteric sites on receptorsCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaDissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domainsMolecular Determinants Underlying Binding Specificities of the ABL Kinase Inhibitors: Combining Alanine Scanning of Binding Hot Spots with Network Analysis of Residue Interactions and CoevolutionDefying c-Abl signaling circuits through small allosteric compounds.Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways.Targeting kinase signaling pathways with constrained peptide scaffolds.Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics.2013 Philip S. Portoghese Medicinal Chemistry Lectureship: drug discovery targeting allosteric sites.Personalized biochemistry and biophysics.Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.Natural course and biology of CML.BCR: a new target in resistance mediated by BCR/ABL-315I?Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors.Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.Opening the door to the development of novel Abl kinase inhibitors.Small-world networks of residue interactions in the Abl kinase complexes with cancer drugs: topology of allosteric communication pathways can determine drug resistance effects.Kinase-templated abiotic reaction.SOCS1 function in BCR-ABL mediated myeloproliferative disease is dependent on the cytokine environment.Bcr-Abl: one kinase, two isoforms, two diseases.Identification and characterization of activating ABL1 1b kinase mutations: impact on sensitivity to ATP-competitive and allosteric ABL1 inhibitors.Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase.Atomic view of the energy landscape in the allosteric regulation of Abl kinase.Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products.Absolute Bioavailability of Bosutinib in Healthy Subjects From an Open-Label, Randomized, 2-Period Crossover Study.Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis.Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.
P2860
Q26768158-BDF3DF4D-E2AC-494E-B60B-F4F283370E67Q27006721-A090108C-F22C-44F6-8A7F-D78D470E0FA3Q27025242-46E823C0-EDFA-43F7-A80C-6A05D0C4B5D2Q27679810-6142DB94-D629-43A4-B76D-2B2831A037A5Q28548366-4ED71ABF-BD45-42E9-AB18-2C83AB931A39Q30009269-07A45A03-F3B1-4F90-923C-DE8529E30545Q30395364-12B3A308-375C-4B68-9398-C02E91A6A75FQ30398451-DE50C19D-88BD-4121-B022-EA95E90C3FD6Q33899740-90D0375E-F1E2-4AF3-B80B-67DBB85570BDQ34243209-FA9307B8-493B-4DF0-984E-C8C17C691DC9Q35558034-FA66146B-60C6-4517-88C3-CDCF01975DCCQ38193659-C6923D81-1B32-4794-AB7A-54BC0823F8F1Q38392667-3FF5B82E-CA3A-4D0E-8FC2-96F84F091694Q38710583-A882B6A8-7B11-4292-8824-B168ACFF23D7Q38734590-DBDC67B8-362F-4862-AAD3-0130D93C0FC2Q38753313-28D8C6F1-C9FE-4B21-B4AA-E3E2CECB094CQ38806783-2424F78B-F1D6-4A6B-BF58-A037625C03A3Q39277365-90974BC5-C9A1-415A-82BD-D19EBA49FC06Q42160458-83634353-DFAE-42FE-B63D-160B4B69F950Q42339101-957F64B9-BBB7-4006-BE71-BA4E52A64C11Q43158736-B76BED06-C026-4CAB-B844-B1F0E4395B8EQ46048561-8390A75E-BC85-41DE-921D-81D4BE7B3DE2Q47093610-103B6D3A-3BA6-49C0-98A5-CD78FBBB5660Q47748395-A8056303-226B-494D-B68F-6FEB68CD6C2EQ49887894-C05A06FE-CDFD-4775-AE4C-F5A2CF285F14Q50068063-30570CB4-2506-4CD1-8B2A-EA4BE27B189DQ50455493-4ED51180-D180-44FD-9599-9C351C7AC4F6Q54117733-844B0657-22B4-4375-BDA8-5759CA8A110D
P2860
Structure, regulation, signaling, and targeting of abl kinases in cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Structure, regulation, signaling, and targeting of abl kinases in cancer.
@ast
Structure, regulation, signaling, and targeting of abl kinases in cancer.
@en
type
label
Structure, regulation, signaling, and targeting of abl kinases in cancer.
@ast
Structure, regulation, signaling, and targeting of abl kinases in cancer.
@en
prefLabel
Structure, regulation, signaling, and targeting of abl kinases in cancer.
@ast
Structure, regulation, signaling, and targeting of abl kinases in cancer.
@en
P2860
P356
P1433
P1476
Structure, regulation, signaling, and targeting of abl kinases in cancer.
@en
P2860
P304
P356
10.1177/1947601912458584
P577
2012-05-01T00:00:00Z